Literature DB >> 33158933

Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction.

John E Sanderson1, Fang Fang2, Mi Lu1, Chen Yao Ma1, Yong Xiang Wei1.   

Abstract

Obstructive sleep apnoea (OSA) is recognised to be a potent risk factor for hypertension, coronary heart disease, strokes and heart failure with a reduced ejection fraction. However, the association between OSA and heart failure with a preserved ejection fraction (HFpEF) is less well recognised. Both conditions are very common globally.It appears that there are many similarities between the pathological effects of OSA and other known aetiologies of HFpEF and its postulated pathophysiology. Intermittent hypoxia induced by OSA leads to widespread stimulation of the sympathetic nervous system, renin-angiotensin-aldosterone system and more importantly a systemic inflammatory state associated with oxidative stress. This is similar to the consequences of hypertension, diabetes, obesity and ageing that are the common precursors to HFpEF. The final common pathway is probably via the development of myocardial fibrosis and structural changes in collagen and myocardial titin that cause myocardial stiffening. Thus, considering the pathophysiology of OSA and HFpEF, OSA is likely to be a significant risk factor for HFpEF and further trials of preventive treatment should be considered. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  heart failure; heart failure with preserved ejection fraction

Year:  2020        PMID: 33158933     DOI: 10.1136/heartjnl-2020-317326

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

Review 1.  Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.

Authors:  Dane Rucker; Jacob Joseph
Journal:  Curr Heart Fail Rep       Date:  2022-09-30

2.  Effect of a Weight Loss and Lifestyle Intervention on Dietary Behavior in Men with Obstructive Sleep Apnea: The INTERAPNEA Trial.

Authors:  Almudena Carneiro-Barrera; Francisco J Amaro-Gahete; Lucas Jurado-Fasoli; Germán Sáez-Roca; Carlos Martín-Carrasco; Francisco J Tinahones; Jonatan R Ruiz
Journal:  Nutrients       Date:  2022-06-30       Impact factor: 6.706

3.  Effects of swimming training on myocardial protection in rats.

Authors:  Chang-Chi Lai; Chia-Yu Tang; Szu-Kai Fu; Wei-Chin Tseng; Kuo-Wei Tseng
Journal:  Biomed Rep       Date:  2022-01-31

4.  Caloric restriction prevents obesity- and intermittent hypoxia-induced cardiac remodeling in leptin-deficient ob/ob mice.

Authors:  Aaron A Jones; Sarah N Framnes-DeBoer; Arianne Shipp; Deanna M Arble
Journal:  Front Physiol       Date:  2022-09-08       Impact factor: 4.755

Review 5.  Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes.

Authors:  Vincenzo Maria Monda; Sandro Gentile; Francesca Porcellati; Ersilia Satta; Alessandro Fucili; Marcello Monesi; Felice Strollo
Journal:  Adv Ther       Date:  2022-09-16       Impact factor: 4.070

Review 6.  COVID-19 and the heart.

Authors:  Andrew Xanthopoulos; Angeliki Bourazana; Grigorios Giamouzis; Evangelia Skoularigki; Apostolos Dimos; Alexandros Zagouras; Michail Papamichalis; Ioannis Leventis; Dimitrios E Magouliotis; Filippos Triposkiadis; John Skoularigis
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

7.  Mining Potential Drug Targets and Constructing Diagnostic Models for Heart Failure Based on miRNA-mRNA Networks.

Authors:  Xiangming Fang; Rensheng Song; Jiaxing Wei; Qin Liao; Zhenhong Zeng
Journal:  Mediators Inflamm       Date:  2022-09-27       Impact factor: 4.529

Review 8.  Obstructive sleep apnea increases the risk of cardiovascular damage: a systematic review and meta-analysis of imaging studies.

Authors:  Mi Lu; Zhenjia Wang; Xiaojun Zhan; Yongxiang Wei
Journal:  Syst Rev       Date:  2021-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.